We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
DelveInsight's 'JAK Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline JAK ...
Global Astrocytoma Market is valued approximately at USD 1.1 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3% over the forecast period 2024-2032. Read the Market ...
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...
A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...
The Zacks Consensus Estimate for Iclusig, Minjuvi and Pemazyre’s third-quarter sales is pegged at $28.1 million, $34.15 million and $22.15 million, respectively. Incremental sales from Zynyz, too, are ...
Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin ...
Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction. If you don't have a login or your access has expired, you will need to ...
MADISON – Council members Eric Range and Melissa Honohan, Democrats who are running uncontested are making appeals to voters ...
Global Klinefelter Syndrome Therapeutics MarketThe global Klinefelter Syndrome Therapeutics Market is projected to surpass ...
A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback